Initially found in non-small cell lung cancer (NSCLC), EML4-ALK fusion has been regarded as an important event in the development of lung cancer and an indication for the application of crizotinib (an ALK inhibitor) [16]. Here, ALK is linked to non-small cell lung carcinoma.